Halozyme Therapeutics, Inc. (HALO) Financial Ratios
25 years of historical data (2001–2025) · Healthcare · Biotechnology
EV/EBITDA
↓
8.34
↓-53% vs avg
5yr avg: 17.83
30Y Low9.1·High42.6
P/FCF
↓
11.91
↓-36% vs avg
5yr avg: 18.65
30Y Low12.9·High114.1
P/B Ratio
↑
165.47
↑+155% vs avg
5yr avg: 64.82
30Y Low5.0·High170.8
ROE
↓
153.6%
-16% vs avg
5yr avg: 183.2%
30Y Low-391%·High231%
Debt/EBITDA
↓
N/A
—
5yr avg: 3.46
30Y Low2.4·High4.7
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HALO Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Halozyme Therapeutics, Inc. trades at 25.5x earnings, 14% above its 5-year average of 22.4x, sitting at the 43rd percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 14%. On a free-cash-flow basis, the stock trades at 11.9x P/FCF, 36% below the 5-year average of 18.6x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.7B | $8.3B | $6.2B | $5.0B | $8.0B | $5.9B | $6.0B | $2.6B | $2.1B | $2.8B | $1.3B |
| Enterprise Value | $7.5B | $8.2B | $7.6B | $6.3B | $9.3B | $6.7B | $6.3B | $2.8B | $2.2B | $2.9B | $1.4B |
| P/E Ratio → | 25.46 | 26.29 | 13.94 | 17.60 | 39.51 | 14.68 | 46.93 | — | — | 45.02 | — |
| P/S Ratio | 5.50 | 5.97 | 6.09 | 5.98 | 12.12 | 13.31 | 22.58 | 13.06 | 13.83 | 8.90 | 8.62 |
| P/B Ratio | 165.47 | 170.83 | 17.01 | 59.18 | 47.12 | 29.97 | 40.00 | 27.89 | 8.44 | 13.52 | — |
| P/FCF | 11.91 | 12.94 | 13.21 | 13.29 | 34.00 | 19.81 | 114.11 | — | — | 21.23 | — |
| P/OCF | 11.78 | 12.80 | 12.92 | 12.76 | 33.32 | 19.71 | 108.95 | — | — | 21.02 | — |
P/E links to full P/E history page with 30-year chart
HALO EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Halozyme Therapeutics, Inc.'s enterprise value stands at 8.3x EBITDA, 53% below its 5-year average of 17.8x. The Healthcare sector median is 14.4x, placing the stock at a 42% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.87 | 7.46 | 7.65 | 14.05 | 15.02 | 23.51 | 14.50 | 14.28 | 9.01 | 9.64 |
| EV / EBITDA | 8.34 | 9.07 | 11.98 | 15.01 | 29.23 | 23.88 | 42.64 | — | — | 34.28 | — |
| EV / EBIT | 9.24 | 10.05 | 13.17 | 17.27 | 34.88 | 26.01 | 42.03 | — | — | 35.20 | — |
| EV / FCF | — | 12.73 | 16.18 | 16.99 | 39.41 | 22.35 | 118.82 | — | — | 21.49 | — |
HALO Profitability
Margins and return-on-capital ratios measuring operating efficiency
Halozyme Therapeutics, Inc. earns an operating margin of 58.4%. Operating margins have expanded from 40.7% to 58.4% over the past 3 years, signaling improving operational efficiency. Return on equity of 153.6% is exceptionally high, though this is partly amplified by negative book value driven by aggressive share buybacks. ROIC of 73.4% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 78.1% | 78.1% | 84.3% | 76.8% | 78.9% | 81.6% | 83.8% | 76.8% | 93.3% | 90.2% | 77.4% |
| Operating Margin | 58.4% | 58.4% | 54.3% | 40.7% | 40.5% | 62.2% | 53.9% | -34.5% | -45.7% | 25.6% | -56.7% |
| Net Profit Margin | 22.7% | 22.7% | 43.7% | 34.0% | 30.6% | 90.8% | 48.2% | -36.9% | -52.9% | 19.9% | -70.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 153.6% | 153.6% | 198.4% | 222.1% | 110.2% | 231.4% | 106.3% | -42.4% | -35.1% | 71.6% | -1959.0% |
| ROA | 13.8% | 13.8% | 23.4% | 15.8% | 13.7% | 47.8% | 22.5% | -14.4% | -16.7% | 16.1% | -46.5% |
| ROIC | 73.4% | 73.4% | 25.7% | 17.4% | 16.7% | 30.5% | 27.9% | -14.7% | -18.6% | 33.8% | -74.8% |
| ROCE | 38.2% | 38.2% | 31.1% | 20.3% | 19.8% | 48.2% | 45.2% | -17.5% | -20.4% | 27.2% | -51.0% |
HALO Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $134M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 45.0x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 4.14 | 17.89 | 8.87 | 4.45 | 2.63 | 4.39 | 0.51 | 0.97 | — |
| Debt / EBITDA | — | — | 2.38 | 3.55 | 4.75 | 3.14 | 2.69 | — | — | 2.43 | — |
| Net Debt / Equity | — | -2.74 | 3.82 | 16.48 | 7.49 | 3.85 | 1.65 | 3.08 | 0.28 | 0.16 | — |
| Net Debt / EBITDA | -0.15 | -0.15 | 2.20 | 3.27 | 4.01 | 2.72 | 1.69 | — | — | 0.40 | — |
| Debt / FCF | — | -0.21 | 2.97 | 3.70 | 5.41 | 2.54 | 4.71 | — | — | 0.25 | — |
| Interest Coverage | 45.03 | 45.03 | 30.48 | 17.99 | 15.79 | 36.66 | 7.08 | -5.81 | -3.84 | 3.68 | -4.17 |
Net cash position: cash ($134M) exceeds total debt ($0)
HALO Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Halozyme Therapeutics, Inc.'s current ratio of 4.66x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 3.66x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 6.64x to 4.66x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.66 | 4.66 | 7.80 | 6.64 | 5.65 | 7.91 | 1.32 | 6.35 | 2.86 | 3.89 | 4.70 |
| Quick Ratio | 3.66 | 3.66 | 6.78 | 5.50 | 4.88 | 7.45 | 1.17 | 6.00 | 2.71 | 3.85 | 4.43 |
| Cash Ratio | 0.81 | 0.81 | 4.29 | 2.99 | 2.77 | 6.32 | 0.87 | 4.92 | 2.37 | 3.57 | 3.76 |
| Asset Turnover | — | 0.55 | 0.49 | 0.48 | 0.36 | 0.40 | 0.46 | 0.35 | 0.34 | 0.61 | 0.56 |
| Inventory Turnover | 1.73 | 1.73 | 1.12 | 1.51 | 1.39 | 1.51 | 0.71 | 1.55 | 0.45 | 6.05 | 2.27 |
| Days Sales Outstanding | — | 115.33 | 110.89 | 103.09 | 127.77 | 74.90 | 133.30 | 110.70 | 72.12 | 25.52 | 39.02 |
HALO Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Halozyme Therapeutics, Inc. returns 4.5% to shareholders annually primarily through share buybacks. The earnings yield of 3.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.9% | 3.8% | 7.2% | 5.7% | 2.5% | 6.8% | 2.1% | — | — | 2.2% | — |
| FCF Yield | 8.4% | 7.7% | 7.6% | 7.5% | 2.9% | 5.0% | 0.9% | — | — | 4.7% | — |
| Buyback Yield | 4.5% | 4.1% | 4.0% | 8.1% | 2.5% | 5.9% | 2.5% | 7.8% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 4.5% | 4.1% | 4.0% | 8.1% | 2.5% | 5.9% | 2.5% | 7.8% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $124M | $129M | $134M | $141M | $147M | $141M | $144M | $144M | $139M | $128M |
Peer Comparison
Compare HALO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HALOYou | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 IONS | $13B | -31.9 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 EXEL | $12B | 16.6 | 12.7 | 13.9 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 AMGN | $178B | 23.1 | 14.1 | 21.9 | 70.8% | 29.1% | 106.1% | 14.8% | 3.4 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 JAZZ | $14B | -38.9 | 23.8 | 11.0 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 25 years · Updated daily
See HALO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HALO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HALO vs ALNY
Side-by-side business, growth, and profitability comparison vs Alnylam Pharmaceuticals, Inc..
Start ComparisonHALO — Frequently Asked Questions
Quick answers to the most common questions about buying HALO stock.
What is Halozyme Therapeutics, Inc.'s P/E ratio?
Halozyme Therapeutics, Inc.'s current P/E ratio is 25.5x. The historical average is 29.1x. This places it at the 43th percentile of its historical range.
What is Halozyme Therapeutics, Inc.'s EV/EBITDA?
Halozyme Therapeutics, Inc.'s current EV/EBITDA is 8.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 23.7x.
What is Halozyme Therapeutics, Inc.'s ROE?
Halozyme Therapeutics, Inc.'s return on equity (ROE) is 153.6%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -32.3%.
Is HALO stock overvalued?
Based on historical data, Halozyme Therapeutics, Inc. is trading at a P/E of 25.5x. This is at the 43th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Halozyme Therapeutics, Inc.'s profit margins?
Halozyme Therapeutics, Inc. has 78.1% gross margin and 58.4% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.